Johanna C Bendell Selected Research

Vomiting

1/2020	First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
1/2019	A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
2/2017	A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
1/2017	First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
3/2016	A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.
4/2013	Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johanna C Bendell Research Topics

Disease

84	Neoplasms (Cancer) 04/2022 - 06/2003
37	Colorectal Neoplasms (Colorectal Cancer) 04/2022 - 02/2006
14	Fatigue 03/2022 - 01/2013
12	Disease Progression 01/2021 - 11/2011
12	Adenocarcinoma 10/2020 - 03/2007
11	Nausea 03/2022 - 01/2013
8	Diarrhea 01/2022 - 12/2013
8	Neutropenia 01/2021 - 09/2012
7	Neoplasm Metastasis (Metastasis) 01/2021 - 06/2003
7	Thrombocytopenia (Thrombopenia) 01/2019 - 07/2012
7	Rectal Neoplasms (Rectal Cancer) 09/2017 - 02/2006
6	Exanthema (Rash) 03/2022 - 02/2011
6	Vomiting 01/2020 - 04/2013
6	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019 - 05/2007
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 01/2016
5	Anemia 01/2022 - 01/2014
5	Carcinoma (Carcinomatosis) 04/2013 - 05/2005
4	Hypertension (High Blood Pressure) 01/2021 - 07/2017
4	Edema (Dropsy) 01/2020 - 01/2014
4	Mucositis 02/2015 - 02/2011
4	Esophageal Neoplasms (Esophageal Cancer) 07/2012 - 03/2007
3	Ovarian Neoplasms (Ovarian Cancer) 11/2020 - 03/2016
3	Wounds and Injuries (Trauma) 01/2019 - 06/2013
3	Asthenia 01/2019 - 01/2013
3	Febrile Neutropenia 08/2013 - 03/2008
3	Pathologic Complete Response 03/2008 - 03/2007
2	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2019
2	Brain Neoplasms (Brain Tumor) 01/2022 - 06/2003
2	Stomach Neoplasms (Stomach Cancer) 11/2021 - 01/2020
2	Colonic Neoplasms (Colon Cancer) 10/2021 - 01/2021
2	Anorexia 01/2020 - 03/2016
2	Stomatitis 01/2019 - 01/2015
2	Melanoma (Melanoma, Malignant) 12/2015 - 08/2012
2	Inflammation (Inflammations) 12/2015 - 04/2003
2	Uveitis 02/2015 - 06/2013
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2008 - 03/2007
2	Anus Neoplasms (Anal Cancer) 05/2007 - 04/2003

Drug/Important Bio-Agent (IBA)

29	Bevacizumab (Avastin)FDA Link 04/2022 - 06/2007
15	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 06/2007
13	Fluorouracil (Carac)FDA LinkGeneric 10/2021 - 04/2003
11	Irinotecan (Camptosar)FDA LinkGeneric 07/2016 - 08/2007
11	Capecitabine (Xeloda)FDA Link 12/2015 - 02/2006
9	Biomarkers (Surrogate Marker)IBA 11/2021 - 06/2013
9	Cetuximab (Erbitux)FDA Link 01/2021 - 08/2007
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2020 - 06/2007
6	Everolimus FDA Link 01/2022 - 01/2011
6	Panitumumab (Vectibix)FDA Link 01/2021 - 01/2011
6	Gemcitabine FDA Link 01/2019 - 01/2011
5	trifluridine tipiracil drug combinationIBA 01/2021 - 11/2015
5	Monoclonal AntibodiesIBA 01/2020 - 04/2013
5	Pharmaceutical PreparationsIBA 01/2020 - 08/2007
5	Carboplatin (JM8)FDA LinkGeneric 01/2018 - 03/2007
5	Paclitaxel (Taxol)FDA LinkGeneric 09/2012 - 03/2007
4	Phosphotransferases (Kinase)IBA 01/2022 - 10/2015
4	Leucovorin (Folinic Acid)FDA Link 01/2021 - 03/2008
4	trametinibIBA 01/2020 - 08/2012
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 08/2012
3	Circulating Tumor DNAIBA 04/2022 - 01/2020
3	NivolumabIBA 03/2022 - 01/2021
3	Transaminases (Aminotransferases)IBA 01/2022 - 06/2013
3	pembrolizumabIBA 11/2021 - 01/2020
3	prexasertibIBA 01/2021 - 01/2020
3	dabrafenibIBA 01/2020 - 12/2015
3	Biological ProductsIBA 01/2020 - 09/2013
3	130-nm albumin-bound paclitaxelIBA 01/2019 - 12/2017
3	Messenger RNA (mRNA)IBA 12/2017 - 01/2013
3	ErbB Receptors (EGF Receptor)IBA 03/2016 - 02/2006
2	SteamIBA 04/2022 - 01/2020
2	LY3023414IBA 01/2022 - 01/2018
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2021 - 10/2020
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 11/2007
2	Pemetrexed (MTA)FDA Link 01/2021 - 08/2013
2	atezolizumabIBA 11/2020 - 01/2016
2	RamucirumabIBA 10/2020 - 01/2019
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 06/2003
2	Differentiation AntigensIBA 01/2020 - 08/2014
2	regorafenibIBA 01/2019 - 10/2015
2	ME-344IBA 10/2017 - 04/2015
2	Axitinib (AG 013736)IBA 07/2017 - 12/2013
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2017 - 09/2013
2	onartuzumabIBA 01/2017 - 09/2013
2	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 07/2016 - 01/2015
2	AntigensIBA 01/2016 - 01/2009
2	TOR Serine-Threonine KinasesIBA 01/2016 - 10/2015
2	KRN-330IBA 08/2014 - 04/2013
2	NVP-BKM120IBA 08/2014 - 01/2012
2	Angiogenesis InhibitorsIBA 08/2013 - 08/2007
2	PanobinostatIBA 09/2012 - 03/2011
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2012 - 02/2011
2	Dihydrotachysterol (AT 10)IBA 07/2012 - 09/2011
1	Androgen Receptors (Androgen Receptor)IBA 01/2022

Therapy/Procedure

33	Therapeutics 03/2022 - 06/2003
28	Drug Therapy (Chemotherapy) 01/2021 - 04/2003
14	Radiotherapy 01/2019 - 04/2003
5	Neoadjuvant Therapy 10/2017 - 08/2007
3	Chemoradiotherapy 01/2009 - 11/2007
2	Castration 01/2022 - 01/2019
2	Adjuvant Chemotherapy 01/2021 - 06/2007
2	Esophagectomy 03/2008 - 03/2007
2	Proctectomy 05/2007 - 04/2003